Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Gaurav      Sharma; Abhishek      Sharma
doi:10.2174/1573402119666230707120846
Abstract

Hypertension is a significant hazardous aspect for several diseases, like cardiovascular disease, kidney failure, and brain disease. Hypertension has become the most lethal condition globally, affecting approximately 1 billion people aged around 30-79 years worldwide. In the year 2022, India was ranked 170th for men and 193rd for women for HTN diagnosis rates among 200 countries worldwide. The main risk factor for cardiac failure and stroke is hypertension. The conventional classes of antihypertensive medications currently available have some side effects. Previously, hypertension has been discussed by various researchers using conventional drug-targeting methods such as ACE inhibitors, aldosterone inhibitors, or renin inhibitors. Recently, novel drug delivery technologies utilizing nanoparticles and new pharmacological classes like ACE2 and APA inhibitors have been studied for the medication of hypertension. In this review, we have covered the epidemiology of hypertension in India, its pathophysiology, medications used in the management of hypertension using nanotechnology, and antihypertensive drugs currently available in the market that are approved and patented. Finally, we have covered how hypertension can be managed with the help of smart devices and artificial intelligence (AI) for improved therapy.
Keywords: Hypertension, pathophysiology, anti-hypertensive, treatment, nanotechnology, artificial intelligence.
« Previous Next »
Graphical Abstract

[1]
Roth GA, Abate D, Abate KH. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet  2018; 392(10159): 1736-88.
 [http://dx.doi.org/10.1016/S0140-6736(18)32203-7] [PMID: 30496103]

[2]
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet  2005; 365(9455): 217-23.
 [http://dx.doi.org/10.1016/S0140-6736(05)17741-1] [PMID: 15652604]

[3]
Forouzanfar MH, Liu P, Roth GA. et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA  2017; 317(2): 165-82.
 [http://dx.doi.org/10.1001/jama.2016.19043] [PMID: 28097354]

[4]
Geldsetzer P, Manne-Goehler J, Marcus ME. et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet  2019; 394(10199): 652-62.
 [http://dx.doi.org/10.1016/S0140-6736(19)30955-9] [PMID: 31327566]

[5]
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol  2020; 16(4): 223-37.
 [http://dx.doi.org/10.1038/s41581-019-0244-2] [PMID: 32024986]

[6]
Zhou B, Bentham J, Di Cesare M. et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet  2017; 389(10064): 37-55.
 [http://dx.doi.org/10.1016/S0140-6736(16)31919-5] [PMID: 27863813]

[7]
Chobanian AV, Bakris GL, Black HR. et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension  2003; 42(6): 1206-52.
 [http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]

[8]
Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension  2017; 70(4): 660-7.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.07802] [PMID: 28784646]

[9]
O’Brien E, Parati G, Stergiou G. et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens  2013; 31(9): 1731-68.
 [http://dx.doi.org/10.1097/HJH.0b013e328363e964] [PMID: 24029863]

[10]
Williamson JD, Supiano MA, Applegate WB. et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. JAMA  2016; 315(24): 2673-82.
 [http://dx.doi.org/10.1001/jama.2016.7050] [PMID: 27195814]

[11]
Zhou B, Bentham J, Di Cesare M. et al. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants. Int J Epidemiol  2018; 47(3): 872-883i.
 [http://dx.doi.org/10.1093/ije/dyy016] [PMID: 29579276]

[12]
Zhou B, Wang H, Yang J. et al. How can China benefit from the achievement of the 25×25 hypertension control goal in 2025? BMC Med  2017; 15(1): 32.
 [http://dx.doi.org/10.1186/s12916-017-0798-z] [PMID: 28193219]

[13]
Anchala R, Kannuri NK, Pant H. et al. Prevalence of hypertension and its association with obesity: A cross-sectional survey in urban and rural Rajasthan. J Hum Hypertens  2015; 29(9): 592-9.
 [http://dx.doi.org/10.1038/jhh.2014.125]

[14]
Dandona L, Dandona R, Kumar GA. et al. India State-Level Disease Burden Initiative Collaborators. Nations within a nation: variations in epidemiological transition across the states of India, 1990–2016 in the Global Burden of Disease Study. Lancet  2017; 390(10111): 2437-60.
 [http://dx.doi.org/10.1016/S0140-6736(17)32804-0] [PMID: 29150201]

[15]
Anchala R, Kannuri NK, Pant H. et al. Hypertension in India. J Hypertens  2014; 32(6): 1170-7.
 [http://dx.doi.org/10.1097/HJH.0000000000000146] [PMID: 24621804]

[16]
Mohanan PP. Cardiology blooms at ACC 2014 at Washington DC but no cherry blossoms. Indian Heart J  2014; 66(2): 253-4.
 [http://dx.doi.org/10.1016/j.ihj.2014.04.002]

[17]
Thankappan KR, Shah B, Mathur P, Sarma PS, Srinivas G, Mini GK. Prevalence, awareness, treatment, and control of hypertension in a rural population in South India. J Hum Hypertens  2006; 20(5): 383-7.
 [http://dx.doi.org/10.1038/sj.jhh.1001984]

[18]
ICMR-INDIAB Collaborative Study Group. Prevalence of hypertension in Indian adults: Results from the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. J Hum Hypertens  2015; 29(4): 204-9.
 [http://dx.doi.org/10.1038/jhh.2014.57]

[19]
Mohan B, Kumar N, Aslam N. et al. Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J  2004; 56(4): 310-4.
 [http://dx.doi.org/10.1016/S0019-4832(04)70088-5] [PMID: 15586739]

[20]
Choudhary M, Gupta SP, Yadav R. et al. Medication adherence and its association with blood pressure control among hypertensive patients attending a tertiary care hospital. J Clin Diagn Res  2017; 11(7): OC05-8.
 [http://dx.doi.org/10.7860/JCDR/2017/27585.10133]

[21]
Kario K. Essential hypertension: Pathophysiology and clinical management. Lancet  2015; 386(9995): 1545-61.
 [http://dx.doi.org/10.1016/S0140-6736(15)60734-3]

[22]
Khera R, Lu Y, Lu J. et al. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: Nationally representative cross sectional study. BMJ  2018; 362: k2357.
 [http://dx.doi.org/10.1136/bmj.k2357] [PMID: 29997129]

[23]
Rubio-Guerra AF. New guides of American College of Cardiology/American Heart Association hypertension for the treatment of high blood pressure. A jump in the right direction? Medicina Interna de México  2018; 34(2)
 [http://dx.doi.org/10.24245/mim.v34i2.2015]

[24]
Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: Individualized patterns of regulation and their implications. Hypertension  2010; 56(1): 10-6.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.140186] [PMID: 20497993]

[25]
Delacroix S, Chokka RG. Hypertension: Pathophysiology and treatment. J Neurol Neurophysiol  2014; 5(6)
 [http://dx.doi.org/10.4172/2155-9562.1000250]

[26]
Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: Therapeutic potentials and limitations. J Nephrol  2020; 33(5): 949-63.
 [http://dx.doi.org/10.1007/s40620-020-00803-3] [PMID: 32681470]

[27]
Miguel-Jiménez S, Carvajal-Serna M, Calvo S. et al. Does melatonin exert its effect on ram sperm capacitation through nitric oxide synthase regulation? Int J Mol Sci  2020; 21(6): 2093.
 [http://dx.doi.org/10.3390/ijms21062093] [PMID: 32197481]

[28]
Ghatage T, Goyal SG, Dhar A, Bhat A. Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies. Hypertens Res  2021; 44(7): 740-55.
 [http://dx.doi.org/10.1038/s41440-021-00643-z] [PMID: 33731923]

[29]
Chen X, Du J, Wu X, Cao W, Sun S. Global burden attributable to high sodium intake from 1990 to 2019. Nutr Metab Cardiovasc Dis  2021; 31(12): 3314-21.
 [http://dx.doi.org/10.1016/j.numecd.2021.08.033] [PMID: 34627699]

[30]
Tanaka M, Itoh H. Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep  2019; 21(8): 63.
 [http://dx.doi.org/10.1007/s11906-019-0964-5] [PMID: 31236708]

[31]
Marques da Silva P, Lima MJ, Neves PM, Espiga de Macedo M. Prevalence of cardiovascular risk factors and other comorbidities in patients with hypertension in Portuguese primary health care populations: The PRECISE study. Revista Portuguesa de Cardiologia  2019; 38(6): 427-37.
 [http://dx.doi.org/10.1016/j.repce.2018.09.012] [PMID: 31307727]

[32]
Litwin M. Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol  2021; 36(4): 825-37.
 [http://dx.doi.org/10.1007/s00467-020-04579-3] [PMID: 32388582]

[33]
Chung AA, Millner PR. Accessory renal artery stenosis and secondary hypertension. Case Rep Nephrol  2020; 2020: 1-4.
 [http://dx.doi.org/10.1155/2020/8879165] [PMID: 32774955]

[34]
Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension  2018; 71(6): 1269-324.
 [http://dx.doi.org/10.1161/HYP.0000000000000066] [PMID: 29133354]

[35]
Gupta R, Malhotra A, Malhotra P. Study of prescribing pattern of drugs used in the treatment of hypertension in a tertiary care teaching hospital in North India: an observational study. J Res Med Sci  2018; 6(7): 2380.
 [http://dx.doi.org/10.18203/2320-6012.ijrms20182821]

[36]
Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Libr  2018; 2018(4): CD001841.
 [http://dx.doi.org/10.1002/14651858.CD001841.pub3] [PMID: 29667175]

[37]
Bhusal M, Aryal E, Bhattarai S, Shrestha SB, Rajouria A. Iatrogenic Cushing syndrome due to application of potent topical corticosteroid: A case report. Nepal Journal of Dermatology. Venereology & Leprology  2019; 17(1): 73-5.
 [http://dx.doi.org/10.3126/njdvl.v17i1.23291]

[38]
Roush GC, Sica DA. Diuretics for hypertension: A review and update. Am J Hypertens  2016; 29(10): 1130-7.
 [http://dx.doi.org/10.1093/ajh/hpw030] [PMID: 27048970]

[39]
Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol  2019; 14(5): 757-64.
 [http://dx.doi.org/10.2215/CJN.04330418] [PMID: 30425103]

[40]
Kochetkov AI. Thiazide and thiazide-like diuretics in the treatment of arterial hypertension: Are there any differences? Ration Pharmacother Cardiol  2020; 16(6): 994-1001.
 [http://dx.doi.org/10.20996/1819-6446-2020-16-09]

[41]
Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother  2014; 15(5): 605-21.
 [http://dx.doi.org/10.1517/14656566.2014.879117] [PMID: 24456327]

[42]
Thakur R, Sharma A. An overview of mucoadhesive thermoreversible nasal gel. Asian J Pharm Res Dev  2021; 9(4): 158-68.

[43]
Martins VM, Ziegelmann PK, Helal L. et al. Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: Protocol for a systematic review and network meta-analysis. Syst Rev  2022; 11(1): 23.
 [http://dx.doi.org/10.1186/s13643-022-01890-y] [PMID: 35135630]

[44]
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Libr  2017; 2017(1): CD002003.
 [http://dx.doi.org/10.1002/14651858.CD002003.pub5] [PMID: 28107561]

[45]
Sari OM. Studi penggunaan obat golongan beta-blocker pada pasien Rawat inap rumah sakit Ansari Saleh Banjarmasin. J Farmasi Udayana 2020.
 [http://dx.doi.org/10.24843/JFU.2020.v09.i02.p07]

[46]
Kaplowitz GJ. Dental management of the medically compromised patient. 1997.
 [http://dx.doi.org/10.14219/jada.archive.1997.0331]

[47]
Frishman WH. Beta-adrenergic blockers. mechanism of action, pharmacokinetics, clinical indications, side effects, and contradictions. Cardiol Clin  1998; 16(3): 429-44.
 [http://dx.doi.org/10.1016/s0733-8651(05)70052-6]

[48]
Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Libr  2020; 2020(10): CD012569.
 [http://dx.doi.org/10.1002/14651858.CD012569.pub2] [PMID: 33089502]

[49]
Daskaya-Dikmen C, Yucetepe A, Karbancioglu-Guler F, Daskaya H, Ozcelik B. Angiotensin-I-converting enzyme (ACE)-inhibitory peptides from plants. Nutrients  2017; 9(4): 316.
 [http://dx.doi.org/10.3390/nu9040316] [PMID: 28333109]

[50]
Agarwal S, Thakur A, Sharma A. Development and evaluation of ketoprofen loaded floating microspheres for sustained delivery. Mater Today Proc  2022; 68: 647-52.
 [http://dx.doi.org/10.1016/j.matpr.2022.05.299]

[51]
Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med  2019; 86(9): 601-7.
 [http://dx.doi.org/10.3949/ccjm.86a.18024] [PMID: 31498767]

[52]
Meng J, Xiao G, Zhang J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect  2020; 9(1): 757-60.
 [http://dx.doi.org/10.1080/22221751.2020.1746200] [PMID: 32228222]

[53]
Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol  2017; 8: 286.
 [http://dx.doi.org/10.3389/fphar.2017.00286]

[54]
Chen N, Zhou M, Yang M. et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Libr  2010; (8): CD003654.
 [http://dx.doi.org/10.1002/14651858.CD003654.pub4] [PMID: 20687074]

[55]
Sharma A, Harikumar SL. Quality by design approach for development and optimization of nitrendipine-loaded niosomal gel for accentuated transdermal delivery. Int J Appl Pharm  2020; 12(5): 181-9.
 [http://dx.doi.org/10.22159/ijap.2020v12i5.38639]

[56]
Sharma A, Singh AP, Harikumar SL. Development and optimization of nanoemulsion based gel for enhanced transdermal delivery of nitrendipine using box-behnken statistical design. Drug Dev Ind Pharm  2020; 46(2): 329-42.
 [http://dx.doi.org/10.1080/03639045.2020.1721527] [PMID: 31976777]

[57]
Sharma A, Sharma R, Singh Bora K, Harikumar SL. Pharmacokinetic investigation of nitrendipine encapsulated niosomal gel in rat plasma by RP-HPLC method. Mater Today Proc  2022; 68: 653-7.
 [http://dx.doi.org/10.1016/j.matpr.2022.05.301]

[58]
Lepor H. Alpha-blockers in the treatment of benign prostatic hyperplasia: mechanism of action, efficacy, and safety. Rev Urol  2007; 9 (Suppl. 3): S18-25.
 [http://dx.doi.org/10.3909/riu0155]

[59]
Saruta T. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Jpn J Clin Med  2005; 63(6): 952-8.
 [http://dx.doi.org/10.1038/hr.2014.68] [PMID: 15948375]

[60]
Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens  2017; 11(1): 54-65.
 [http://dx.doi.org/10.1016/j.jash.2016.11.007] [PMID: 28057444]

[61]
Mulder E, Ghossein-Doha C, Appelman E. et al. Study protocol for the randomized controlled EVA (early vascular adjustments) trial: tailored treatment of mild hypertension in pregnancy to prevent severe hypertension and preeclampsia. BMC Pregnancy Childbirth  2020; 20(1): 775.
 [http://dx.doi.org/10.1186/s12884-020-03475-w] [PMID: 33308198]

[62]
Tarkin JM, Kaski JC. Vasodilator therapy: Nitrates and nicorandil. Cardiovasc Drugs Ther  2016; 30(4): 367-78.
 [http://dx.doi.org/10.1007/s10557-016-6668-z] [PMID: 27311574]

[63]
Kincaid-Smith P. Vasodilator drugs in the treatment of hypertension. Med J Aust  1985; 142(8): 450-3.
 [http://dx.doi.org/10.5694/j.1326-5377.1985.tb113448.x] [PMID: 3884988]

[64]
Nappi J, Sieg A. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. Vasc Health Risk Manag  2011; 7(1): 353-63.
 [http://dx.doi.org/10.2147/VHRM.S13779] [PMID: 21731887]

[65]
Gao Q, Xu L, Cai J. New drug targets for hypertension: A literature review. Biochim Biophys Acta Mol Basis Dis  2021; 1867(3): 166037.
 [http://dx.doi.org/10.1016/j.bbadis.2020.166037] [PMID: 33309796]

[66]
Nadeem S, Batisky DL. Aliskiren, the first direct renin inhibitor: Assessing a role in pediatric hypertension and kidney diseases. Pediatr Nephrol  2014; 29(11): 2105-11.
 [http://dx.doi.org/10.1007/s00467-013-2716-0] [PMID: 24337365]

[67]
Ramya K, Suresh R, Kumar HY, Kumar BRP, Murthy NBS. Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. Bioorg Med Chem  2020; 28(10): 115466.
 [http://dx.doi.org/10.1016/j.bmc.2020.115466] [PMID: 32247750]

[68]
Leontsinis I, Mantzouranis M, Tsioufis P, Andrikou I, Tsioufis C. Recent advances in managing primary hypertension. Fac Rev  2020; 9: 4.
 [http://dx.doi.org/10.12703/b/9-4] [PMID: 33659936]

[69]
Szeto CC, Sugano K, Wang JG. et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: Joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut  2020; 69(4): 617-29.
 [http://dx.doi.org/10.1136/gutjnl-2019-319300] [PMID: 31937550]

[70]
Kitt J, Fox R, Tucker KL, McManus RJ. New approaches in hypertension management: A review of current and developing technologies and their potential impact on hypertension care. Curr Hypertens Rep  2019; 21(6): 44.
 [http://dx.doi.org/10.1007/s11906-019-0949-4] [PMID: 31025117]

[71]
Adetunji CO, Michael OS, Rathee S. et al. Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. Materials Today Advances  2022; 13: 100198.
 [http://dx.doi.org/10.1016/j.mtadv.2021.100198]

[72]
Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res  2015; 116(6): 1074-95.
 [http://dx.doi.org/10.1161/CIRCRESAHA.116.303603] [PMID: 25767291]

[73]
Jackson TC, Patani BO, Ekpa DE. Nanotechnology in diagnosis: A review. Adv Nanopart  2017; 6(3): 93-102.
 [http://dx.doi.org/10.4236/anp.2017.63008]

[74]
Davis J, Oparil S. Novel medical treatments for hypertension and related comorbidities. Curr Hypertens Rep  2018; 20(10): 90.
 [http://dx.doi.org/10.1007/s11906-018-0890-y] [PMID: 30145617]

[75]
Sharma A, Babu Sharma R, Verma A, Thakur R. Insight on nanoparticles, green synthesis and applications in drug delivery system-a comprehensive review. Int J Life Sci Pharma Res  2022; 12(5): 68-84.
 [http://dx.doi.org/10.22376/ijpbs/lpr.2022.12.5.P68-84]

[76]
Zhang Y, Wang Q, Li H. et al. Design and evaluation of a biodegradable PLGA-based nanosuspension for the delivery of an anti-cancer agent. J Biomed Nanotechnol  2022; 18: 660.
 [http://dx.doi.org/10.1166/jbn.2022.3413]

[77]
Li Y, Wang L, Li Y. et al. Preparation and characterization of chitosan-coated magnetic nanoparticles for drug delivery applications. Particuology  2022; 64: 153.
 [http://dx.doi.org/10.1016/j.partic.2022.02.001]

[78]
Ekambaram P, Abdul Hasan Sathali A. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm  2011; 3(3): 216-20.
 [http://dx.doi.org/10.4103/0975-1483.83765] [PMID: 21897661]

[79]
Chonkar AD, Rao JV, Managuli RS. et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. Eur J Pharm Biopharm  2016; 103: 179-91.
 [http://dx.doi.org/10.1016/j.ejpb.2016.04.001] [PMID: 27063592]

[80]
Kara A, Vassiliadou A, Ongoren B. et al. Engineering 3d printed microfluidic chips for the fabrication of nanomedicines. Pharmaceutics  2021; 13(12): 2134.
 [http://dx.doi.org/10.3390/pharmaceutics13122134] [PMID: 34959415]

[81]
Choudhary R, Bodla RB, Gupta G. et al. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz J Infect Dis  2018; 22(2): 86-99.
 [http://dx.doi.org/10.1016/j.bjid.2018.02.001]

[82]
Prajapati JB, Katariya H, Patel R. Peyer’e patch targeting of isradipine loaded Solid Lipid Nanoparticles: it’s cellular uptake study. Journal of Drug Delivery ADVERSE EVENTS: A SYSTEMATIC META-ANALYSIS. J Am Coll Cardiol  2018; 69(11)
 [http://dx.doi.org/10.1016/S0735-1097(17)34307-3]

[83]
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: Characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv  2016; 23(2): 395-404.
 [http://dx.doi.org/10.3109/10717544.2014.914986] [PMID: 24865287]

[84]
Sharma A, Thakur R, Sharma R. Development and optimization of candesartan cilexetil nasal gel for accentuated intranasal delivery using central composite design. Mater Today Proc 2022. In Press
 [http://dx.doi.org/10.1016/j.matpr.2022.11.221]

[85]
Shirisha S, Saraswathi A, Sahoo SK, Rao YM. Formulation and evaluation of nisoldipine loaded solid lipid nanoparticles and nanostructured lipid carriers: application to transdermal delivery. Indian J Pharm Educ Res  2020; 54(2s): s117-27.
 [http://dx.doi.org/10.5530/ijper.54.2s.68]

[86]
Suthar V, Butani S, Gohel M. Solid self-emulsified nanostructures of Lercanidipine hydrochloride: A potential approach to improve the fraction of the dose absorbed. J Drug Deliv Sci Technol  2016; 31: 11-21.
 [http://dx.doi.org/10.1016/j.jddst.2015.11.001]

[87]
Kataria D, Zafar A, Ali J. et al. Formulation of lipid-based nanocarriers of lacidipine for improvement of oral delivery: box-Behnken design optimization, in vitro, ex vivo, and preclinical assessment. Assay Drug Dev Technol  2022; 20(1): 5-21.
 [http://dx.doi.org/10.1089/adt.2021.084] [PMID: 34978917]

[88]
Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm  2011; 37(8): 907-16.
 [http://dx.doi.org/10.3109/03639045.2010.550050] [PMID: 21401341]

[89]
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm  2007; 66(2): 227-43.
 [http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045]

[90]
Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv  2017; 24(1): 358-69.
 [http://dx.doi.org/10.1080/10717544.2016.1255999] [PMID: 28165823]

[91]
Abu-Huwaij R, Hamed R, Daoud E, Alkilani A. Development and in vitro characterization of nanoemulsion-based buccal patches of valsartan. Acta Pol Pharm  2019; 76(2): 313-21.
 [http://dx.doi.org/10.32383/appdr/99526]

[92]
Gorain B, Choudhury H, Kundu A. et al. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Colloids Surf B Biointerfaces  2014; 115: 286-94.
 [http://dx.doi.org/10.1016/j.colsurfb.2013.12.016] [PMID: 24388859]

[93]
Dahash RAA, Rajab NA. Formulation and investigation of lacidipine as nanoemulsions. Iraqi J Pharm Sci  2020; 29(1): 41-54.
 [http://dx.doi.org/10.31351/vol29iss1pp41-54]

[94]
Fernandes GJ, Kumar L, Sharma K, Tunge R, Rathnanand M. A review on solubility enhancement of carvedilol-a BCS Class II drug. J Pharm Innov  2018; 13(3): 197-212.
 [http://dx.doi.org/10.1007/s12247-018-9319-z]

[95]
ElKasabgy NA, Elsayed I, Elshafeey AH. Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: In-vitro and in-vivo characterization. Int J Pharm  2014; 472(1-2): 369-79.
 [http://dx.doi.org/10.1016/j.ijpharm.2014.06.048] [PMID: 24979531]

[96]
Burkey BF, Hoglen NC, Inskeep P, Wyman M, Hughes TE, Vath JE. Preclinical efficacy and safety of the novel antidiabetic, antiobesity metap2 inhibitor ZGN-1061. J Pharmacol Exp Ther  2018; 365(2): 301-13.
 [http://dx.doi.org/10.1124/jpet.117.246272] [PMID: 29491038]

[97]
Seth M, Hussain ME, Pasha S, Fahim M. Effects of a novel ACE inhibitor, 3-(3-thienyl)-L-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in L-NAME-induced hypertensive rats. Drug Des Devel Ther  2016; 10: 1533-42.
 [http://dx.doi.org/10.2147/DDDT.S77761] [PMID: 27143859]

[98]
Wilson AJ, Chang B, Chin BC, Taglinenti AJ, Folsom N, Percec I. Abstract 63: A quantitative analysis of different botulinum toxin formulations: A randomized double blind prospective clinical trial of comparative dynamic strain reduction. Plast Reconstr Surg  2015; 135: 50-1.
 [http://dx.doi.org/10.1097/01.prs.0000465511.62305.6c]

[99]
Kim HK, Hwang SH, Abdi S. Tempol ameliorates and prevents mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain. Front Pharmacol  2017; 7(JAN): 532.
 [http://dx.doi.org/10.3389/fphar.2016.00532] [PMID: 28138318]

[100]
Dzhoyashvili N, Iyer S, Chen Y. et al. The novel GC-A/CGMP activating designer M-ATRIAL natriuretic peptide potently reduces blood pressure in a genetic model of hypertension and potentiates the actions of furosemide. J Am Coll Cardiol  2019; 73(9): 1713.
 [http://dx.doi.org/10.1016/S0735-1097(19)32319-8]

[101]
Pozdnyakov Y, Kostyukova A, Khokhlov A. et al. Novel soluble guanylyl cyclase activator for the treatment of hypertension and metabolic syndrome. Eur Heart J  2020; 41 (Suppl_2): ehaa946.1224.
 [http://dx.doi.org/10.1093/ehjci/ehaa946.1224]

[102]
Nesbitt SD. Firibastat: A novel treatment for hypertension. Curr Hypertens Rep  2021; 23(12): 46.
 [http://dx.doi.org/10.1007/s11906-021-01163-4] [PMID: 34950965]

[103]
Barone M. Recombinant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: A theoretical or a real resource?. Eurasian J Med Oncol 2020.
 [http://dx.doi.org/10.14744/ejmo.2020.47992]

[104]
Hanrahan JP, Seferovic JP, Wakefield JD. et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia  2020; 63(4): 733-43.
 [http://dx.doi.org/10.1007/s00125-019-05062-x] [PMID: 31858186]

[105]
Ahmed HA, Ishrat T, Pillai B. et al. RAS modulation prevents progressive cognitive impairment after experimental stroke: A randomized, blinded preclinical trial. J Neuroinflammation  2018; 15(1): 229.
 [http://dx.doi.org/10.1186/s12974-018-1262-x] [PMID: 30103772]

[106]
Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor Tenapanor: two trials in healthy volunteers. Clin Drug Investig  2018; 38(4): 341-51.
 [http://dx.doi.org/10.1007/s40261-017-0614-0] [PMID: 29363027]

[107]
Markham A. Tenapanor: First Approval. Drugs  2019; 79(17): 1897-903.
 [http://dx.doi.org/10.1007/s40265-019-01215-9] [PMID: 31677150]

[108]
Mathews JL, Schweighardt A. The role of natriuretic peptides in the pathophysiology and treatment of heart failure. In: Emerging applications, perspectives, and discoveries in cardiovascular research.  2017.
 [http://dx.doi.org/10.4018/978-1-5225-2092-4.ch001]

[109]
Massie BM, O’Connor CM, Metra M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med  2010; 363(15): 1419-28.
 [http://dx.doi.org/10.1056/NEJMoa0912613] [PMID: 20925544]

[110]
Enevoldsen FC, Sahana J, Wehland M, Grimm D, Infanger M, Krüger M. Endothelin receptor antagonists: Status quo and future perspectives for targeted therapy. J Clin Med  2020; 9(3): 824.
 [http://dx.doi.org/10.3390/jcm9030824] [PMID: 32197449]

[111]
Treiber A, Delahaye S, Seeland S, Gnerre C. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern. Pharmacol Res Perspect  2020; 8(4): e00619.
 [http://dx.doi.org/10.1002/prp2.619] [PMID: 32613761]

[112]
Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: Entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol  2014; 70(12): 1479-86.
 [http://dx.doi.org/10.1007/s00228-014-1755-8] [PMID: 21541781]

[113]
Bartolucci R, Dosne AG, Csonka D, Pérez-Ruixo JJ, Magni P, Poggesi I. A population pharmacokinetic model of macitentan and its active metabolite Aprocitentan in healthy volunteers and patients with pulmonary arterial hypertension. Clin Pharmacokinet  2021; 60(12): 1605-19.
 [http://dx.doi.org/10.1007/s40262-021-01049-3] [PMID: 34159557]

[114]
Wei CY, Tzeng IS, Lin MC, Yeh YH, Hsu CY, Kung WM. Risks of sulpiride-induced Parkinsonism in peptic ulcer and gastroesophageal reflux disease patients in Taiwan: A nationwide population-based study. Front Pharmacol  2020; 11: 433.
 [http://dx.doi.org/10.3389/fphar.2020.00433] [PMID: 32390831]

[115]
Bairwa M, Pilania M, Gupta V, Yadav K. Hypertension Vaccine may be a boon to millions in developing world. Hum Vaccin Immunother  2014; 10(3): 708-13.
 [http://dx.doi.org/10.4161/hv.27520] [PMID: 24365998]

[116]
Maurer P, Bachmann MF. Immunization against angiotensins for the treatment of hypertension. Clin Immunol  2010; 134(1): 89-95.
 [http://dx.doi.org/10.1016/j.clim.2009.06.003] [PMID: 19577521]

[117]
Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens  2014; 8(5): 330-9.
 [http://dx.doi.org/10.1016/j.jash.2014.02.003] [PMID: 24631482]

[118]
Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J  2015; 108(2): 91-6.
 [http://dx.doi.org/10.14423/SMJ.0000000000000235] [PMID: 25688893]

[119]
Sharif NA. Novel potential treatment modalities for ocular hypertension: Focus on angiotensin and bradykinin system axes. J Ocul Pharmacol Ther  2015; 31(3): 131-45.
 [http://dx.doi.org/10.1089/jop.2014.0114] [PMID: 25599263]

[120]
Chen Y, Zheng Y, Iyer SR. et al. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. J Mol Cell Cardiol  2019; 130: 140-50.
 [http://dx.doi.org/10.1016/j.yjmcc.2019.03.024] [PMID: 30954448]

[121]
Yamakawa S, Homma T, Yamada M, Igawa Y, Yoshimura M. Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro<sup>®</sup> tablets 1.25 mg, 2.5 mg, 5 mg). Nippon Yakurigaku Zasshi  2020; 155(5): 340-50.
 [http://dx.doi.org/10.1254/fpj.20016] [PMID: 32879177]

[122]
Pezik E, Gulsun T, Sahin S. Vural İ Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. Eur J Pharm Sci  2021; 156: 105597.
 [http://dx.doi.org/10.1016/j.ejps.2020.105597] [PMID: 33065224]

[123]
Fares H, DiNicolantonio JJ, O’Keefe JH, Lavie CJ. Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart  2016; 3(2): e000473.
 [http://dx.doi.org/10.1136/openhrt-2016-000473] [PMID: 27752334]

[124]
Ma W, Sun N, Duan C. et al. Effectiveness of Levoamlodipine maleate for hypertension compared with amlodipine besylate: a pragmatic comparative effectiveness study. Cardiovasc Drugs Ther  2021; 35(1): 41-50.
 [http://dx.doi.org/10.1007/s10557-020-07054-1] [PMID: 32915349]

[125]
Snelder N, Ploeger BA, Luttringer O. et al. Drug effects on the CVS in conscious rats: Separating cardiac output into heart rate and stroke volume using PKPD modelling. Br J Pharmacol  2014; 171(22): n/a.
 [http://dx.doi.org/10.1111/bph.12824] [PMID: 24962208]

[126]
Saputri FA, Kang D, Kusuma ASW. et al. Lactobacillus plantarum IS-10506 probiotic administration increases amlodipine absorption in a rabbit model. J Int Med Res  2018; 46(12): 5004-10.
 [http://dx.doi.org/10.1177/0300060518788994] [PMID: 30092663]

[127]
Mukherjee D, Zha J, Menon RM, Shebley M. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. J Pharmacokinet Pharmacodyn  2018; 45(3): 443-56.
 [http://dx.doi.org/10.1007/s10928-018-9574-0] [PMID: 29427135]

[128]
Mahmoud AM, Abdel-Wadood HM, Mohamed NA. Kinetic spectrophotometric method for determination of amlodipine besylate in its pharmaceutical tablets. J Pharm Anal  2012; 2(5): 334-41.
 [http://dx.doi.org/10.1016/j.jpha.2012.03.002] [PMID: 29403763]

[129]
Kass RS, Arena JP. Influence of pHo on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J Gen Physiol  1989; 93(6): 1109-27.
 [http://dx.doi.org/10.1085/jgp.93.6.1109] [PMID: 2549176]

[130]
Khemasuwan D, Sorensen JS, Colt HG. Artificial intelligence in pulmonary medicine: Computer vision, predictive model and COVID-19. Eur Respir Rev  2020; 29(157): 200181.
 [http://dx.doi.org/10.1183/16000617.0181-2020] [PMID: 33004526]

[131]
Mueller FB. AI (artificial intelligence) and hypertension research. Curr Hypertens Rep  2020; 22(9): 70.
 [http://dx.doi.org/10.1007/s11906-020-01068-8] [PMID: 32852654]

[132]
Fosso Wamba S, Queiroz MM. Responsible artificial intelligence as a secret ingredient for digital health: Bibliometric analysis, insights, and research directions. Inf Syst Front  2021; •••: 1-16.
 [http://dx.doi.org/10.1007/s10796-021-10142-8] [PMID: 34025210]

[133]
Amaratunga D, Cabrera J, Sargsyan D, Kostis JB, Zinonos S, Kostis WJ. Uses and opportunities for machine learning in hypertension research. Int J Cardiol Hypertens  2020; 5: 100027.
 [http://dx.doi.org/10.1016/j.ijchy.2020.100027] [PMID: 33447756]

[134]
Krittanawong C, Bomback AS, Baber U, Bangalore S, Messerli FH, Wilson Tang WH. Future direction for using artificial intelligence to predict and manage hypertension. Curr Hypertens Rep  2018; 20(9): 75.
 [http://dx.doi.org/10.1007/s11906-018-0875-x] [PMID: 29980865]

[135]
Koshimizu H, Kojima R, Okuno Y. Future possibilities for artificial intelligence in the practical management of hypertension. Hypertens Res  2020; 43(12): 1327-37.
 [http://dx.doi.org/10.1038/s41440-020-0498-x] [PMID: 32655135]

[136]
Andrews LJB, Raja L, Shanmugasundaram S. Mobile android-based remote patient monitoring system through wearable sensors. J Discrete Math Sci Cryptogr  2019; 22(4): 557-68.
 [http://dx.doi.org/10.1080/09720529.2019.1637156]

[137]
Adhikary R, Krishnakumar A, Kolwankar S, Shah A, Sanghavi S, Mattoo V. Effectiveness of digital therapeutics to improve blood pressure control among patients with hypertension and diabetes in India. J Am Coll Cardiol  2020; 75(11): 3583.
 [http://dx.doi.org/10.1016/S0735-1097(20)34210-8]

[138]
Ganti VG, Carek AM, Nevius BN, Heller JA, Etemadi M, Inan OT. Wearable cuff-less blood pressure estimation at home via pulse transit time. IEEE J Biomed Health Inform  2021; 25(6): 1926-37.
 [http://dx.doi.org/10.1109/JBHI.2020.3021532] [PMID: 32881697]

[139]
Alotaibi M, Uddin MA. Effectiveness of e-health systems in improving hypertension management and awareness: A systematic review. Trans Internet Inf Syst  2022; 16(1)
 [http://dx.doi.org/10.3837/tiis.2022.01.010]

[140]
Majumder S. Wearable sensors for monitoring of physiological parameters and algorithms for extraction of clinically relevant information. IEEE Rev Biomed Eng  2017; 10: 86-99.
 [http://dx.doi.org/10.1109/RBME.2017.2769423]

[141]
Elshawi R, Al-Mallah MH, Sakr S. On the interpretability of machine learning-based model for predicting hypertension. BMC Med Inform Decis Mak  2019; 19(1): 146.
 [http://dx.doi.org/10.1186/s12911-019-0874-0] [PMID: 31357998]

[142]
Jha S, Topol EJ. Adapting to artificial intelligence: Radiologists and pathologists as information specialists. JAMA  2016; 316(22): 2353-4.
 [http://dx.doi.org/10.1001/jama.2016.17438] [PMID: 27898975]
Rights & Permissions Print Cite
Article Metrics
30
3
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573402119666230707120846	Print ISSN 1573-4021
Publisher Name Bentham Science Publisher	Online ISSN 1875-6506
Current Hypertension Reviews

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Abstract

Graphical Abstract

Arterial Stiffness in hypertension and left ventricular dysfunction, PWV, Heart Failure

Pediatric Hypertension

Current Hypertension Reviews

Recent Insights on Drug Delivery System in Hypertension: From Bench to Market

Abstract

Graphical Abstract

Call for Papers in Thematic Issues

Arterial Stiffness in hypertension and left ventricular dysfunction, PWV, Heart Failure

Pediatric Hypertension

Related Journals

Related Books

Related Articles
